ARBs Library

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Angiotensin II Receptor Blockers DMPK and Bioanalytical Services

ARB bioanalysis splits across three metabolic routes that a single method cannot serve: CYP-dependent hepatic metabolism (losartan via CYP2C9/CYP3A4, irbesartan via CYP2C9), CYP-independent biliary excretion (valsartan, telmisartan), and esterase-mediated prodrug activation (olmesartan medoxomil → olmesartan). Treating all five ARBs as one analytical class routinely produces data that fail to answer the actual study question.

Creative Proteomics provides ARB-focused DMPK workflows spanning CYP-dependent metabolic profiling, CYP-independent excretion and distribution studies, esterase-stabilized prodrug activation monitoring, and custom multi-ARB panels.

Browse ARB Drug Index Request Custom ARB Method Support

CYP-Dependent vs CYP-Independent Metabolic RoutesSeparate CYP-metabolized substrates (losartan, irbesartan) from CYP-independent biliary-excreted compounds (valsartan, telmisartan).

Esterase Prodrug Activation MonitoringOlmesartan medoxomil requires esterase-stabilized sampling and prodrug-to-active-form quantification.

CYP2C9 Polymorphism ContextLosartan and irbesartan metabolism via CYP2C9 introduces inter-subject variability requiring genotyped study models.

ARB Metabolic Route Risks DMPK Strategy Map

⚡

Metabolic Route ClassificationLosartan and irbesartan follow CYP-dependent hepatic metabolism; valsartan and telmisartan follow CYP-independent biliary/fecal excretion; olmesartan requires esterase activation — three distinct analytical pathways.

🧬

CYP-Dependent Metabolism & MetIDLosartan (CYP2C9, CYP3A4 → active EXP3174) and irbesartan (CYP2C9) require microsome/hepatocyte incubation, Phase I/II metabolite profiling, and CYP isoform-specific study design.

📊

CYP-Independent Excretion & DistributionValsartan and telmisartan are cleared primarily via biliary/fecal excretion with ~20% renal contribution — distribution and excretion workflows without CYP metabolism steps.

🔬

Esterase Prodrug ActivationOlmesartan medoxomil → olmesartan conversion requires esterase-stabilized sample handling and simultaneous prodrug–active metabolite quantification.

ARB-specific metabolic route triage.Creative Proteomics determines whether the compound follows CYP-dependent metabolism, CYP-independent excretion, or esterase-mediated prodrug activation before LC-MS/MS method development begins — because a single generic ARB method cannot serve all three routes.

ARB Drug Index

Find the ARB Compound Behind the Study

ARB studies split by a key analytical question: does the compound follow CYP-dependent hepatic metabolism, CYP-independent biliary/fecal excretion, or esterase-mediated prodrug activation? Use the index to classify the metabolic route, identify the relevant enzyme and system setup, and route the workflow accordingly. The drug panels are intentionally concise so detailed compound monographs can be added separately.

A–Z anchors

Filter by study tagsSelect a field to reveal its tags. Multiple tags work together as narrowing filters, so the drug index shows only ARBs matching all selected values.

5 entries · Page 1 of 3

Analytical Pain Points

What Drives Assay Failure in ARB Studies?

ARBs can fail analytically when a single generic method is used for compounds that differ fundamentally by metabolic route: CYP-dependent hepatic oxidation, CYP-independent biliary/fecal excretion, or esterase-mediated prodrug activation. The key issue is not only detection, but whether the workflow matches the compound’s actual clearance mechanism — and whether CYP2C9 polymorphism, prodrug activation, and excretion endpoints are each handled with the appropriate analytical strategy.

Three Metabolic Routes Demand Three Different Workflows

Losartan and irbesartan require CYP-dependent microsomal/hepatocyte metabolism and MetID. Valsartan and telmisartan need excretion- and distribution-focused bioanalysis without CYP incubation. Olmesartan medoxomil needs esterase-stabilized prodrug activation monitoring. One generic ARB method cannot serve all three.

Our responseMetabolic-route-aware LC-MS/MS workflows that classify each ARB by its clearance mechanism — CYP-dependent, CYP-independent, or esterase-prodrug — before method development begins.

LC-MS/MS Drug Quantification →

CYP2C9 Polymorphism Introduces Inter-Subject Metabolic Variability

Losartan and irbesartan are CYP2C9 substrates. CYP2C9 genetic polymorphism produces substantial inter-individual differences in metabolic rate and metabolite exposure, which can confound pooled-microsome or single-donor hepatocyte study interpretation.

Our responseCYP2C9-genotyped microsome and hepatocyte models with isoform-specific activity verification and metabolite profiling under defined CYP2C9 activity conditions.

Metabolite Identification →

CYP-Independent Compounds Require Excretion-Focused Bioanalysis

Valsartan and telmisartan, cleared primarily via biliary/fecal excretion with negligible CYP involvement, need tissue distribution and excretion profiling that differs fundamentally from metabolism-driven hepatocyte or microsome workflows.

Our responseMatrix-specific bioanalysis for CYP-independent ARBs in plasma, bile, feces, and urine with excretion- and distribution-oriented study design and reporting.

Complex Biological Matrices Analysis →

Olmesartan Medoxomil Requires Esterase-Stabilized Prodrug Activation Monitoring

Olmesartan medoxomil is an esterase-activated prodrug. Without esterase inhibitor during collection, processing, and storage, the prodrug can continue converting to active olmesartan ex vivo — producing artificially elevated active-form concentrations and distorted activation kinetics.

Our responseEsterase-stabilized sampling protocols with simultaneous olmesartan medoxomil–olmesartan quantification, esterase inhibitor-spiked collection, and matrix-matched calibration for prodrug and active form.

Stability Studies →

Multi-ARB Panels Must Handle Mixed Metabolic Routes in One Assay

A panel combining CYP-metabolized substrates (losartan, irbesartan), biliary-excreted parents (valsartan, telmisartan), and an esterase prodrug (olmesartan) needs extraction, chromatography, MRM scheduling, internal standards, and calibration designed for metabolic-route heterogeneity — not five independent single-analyte methods.

Our responseCustom multi-ARB LC-MS/MS panels with extraction and chromatography optimized at panel level, metabolic-route-aware MRM scheduling, and matrix-matched calibration across CYP substrates, biliary-excreted compounds, and esterase prodrugs.

Custom Panels →

Focused Service Paths

Four Practical Routes for ARB Studies

ARB workflows should be selected according to metabolic route: CYP-dependent metabolism and MetID for losartan and irbesartan, CYP-independent excretion and distribution for valsartan and telmisartan, esterase-prodrug activation monitoring for olmesartan, or multi-ARB panels for mixed-route study designs.

CYP-Dependent ARB Metabolism & MetID

For studies requiring CYP-mediated metabolism profiling and metabolite identification for losartan (CYP2C9, CYP3A4) or irbesartan (CYP2C9) in microsome and hepatocyte models.

Phase I and Phase II metabolite profiling
CYP2C9 and CYP3A4 isoform-specific incubation
Active metabolite quantification (EXP3174)
Genotyped microsome / hepatocyte selection

Phase I & II Metabolite Characterization →

CYP-Independent Excretion & Distribution Studies

For valsartan and telmisartan studies where biliary/fecal excretion and tissue distribution are the primary endpoints, not CYP-mediated hepatic metabolism.

Biliary and fecal excretion profiling
Tissue distribution quantification
Plasma pharmacokinetic bioanalysis
Matrix-specific method adaptation

Complex Biological Matrices →

Esterase Prodrug Activation Monitoring

For olmesartan medoxomil studies requiring esterase-stabilized prodrug-to-active-form conversion monitoring and simultaneous prodrug–active metabolite quantification.

Esterase-stabilized prodrug incubation
Simultaneous prodrug–active metabolite quantification
Activation kinetics and conversion rate
Microsome / hepatocyte model selection

Simultaneous Parent-Metabolite Panels →

Custom Multi-ARB Panel Development

For studies involving multiple ARBs across CYP-dependent, CYP-independent, and esterase-prodrug metabolic routes within one validated analytical method.

Multi-ARB LC-MS/MS panel design
Mixed metabolic-route MRM scheduling
CYP substrate + excretion compound + prodrug compatibility
Panel-level extraction and calibration optimization

Custom Multi-Analyte Drug Panels →

Project Inquiry

Need Support for a Novel or Unlisted ARB?

If you are working with a CYP-metabolized ARB requiring isoform-specific MetID, a CYP-independent compound needing excretion and distribution analysis, an esterase-activated prodrug requiring activation monitoring, or a multi-ARB panel spanning mixed metabolic routes, a standard parent-only LC-MS/MS method may not answer the study question.

Creative Proteomics develops custom LC-MS/MS and DMPK workflows by defining the metabolic route, CYP isoforms involved, prodrug or parent-drug status, esterase sensitivity, biological matrix, expected concentration range, and panel compatibility before method development begins.

Target ARB

Metabolic route (CYP / non-CYP / prodrug)

CYP isoform(s) if applicable

Esterase stabilization need

Excretion / distribution focus

Panel requirements